Core Viewpoint - Yongtai Bio-B (06978.HK) has successfully completed its rights issue, with total valid acceptances and applications exceeding the number of shares offered, indicating strong investor interest [1] Group 1: Rights Issue Details - The rights issue was for a total of 102,916,800 shares, with 92,175,828 shares accepted, representing approximately 89.56% of the total offered [1] - Additionally, there were 445,784,230 shares applied for under extra application forms, which is about 433.15% of the total offered shares [1] - In total, there were valid acceptances and applications for 538 million shares, amounting to approximately 522.71% of the total offered shares [1] Group 2: Financial Outcomes - The total proceeds from the rights issue are approximately HKD 257 million, with a net amount expected to be around HKD 252 million after deducting professional fees and other related expenses [1] - The conditions outlined in the rights issue prospectus have been fully met, and the rights issue became unconditional on November 6, 2025 [1]
永泰生物-B(06978.HK)供股获超额认购5.23倍 筹资2.57亿港元